PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.

PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma.

Show other versions (1)

BACKGROUND: PIM serine/threonine kinases are often highly expressed in haematological malignancies. We have shown that PIM inhibitors reduced the survival and migration of leukaemic cells. Here, we investigated PIM kinases in diffuse large B-cell lymphoma (DLBCL) biopsy samples and DLBCL cell lines....

Full description

Bibliographic Details
Main Authors:	Brault, L, Menter, T, Obermann, E, Knapp, S, Thommen, S, Schwaller, J, Tzankov, A
Format:	Journal article
Language:	English
Published:	2012

Similar Items

PIM kinases are progression markers and emerging therapeutic targets in diffuse large B-cell lymphoma
by: Brault, L, et al.
Published: (2012)

PIM serine/threonine kinases in the pathogenesis and therapy of hematologic malignancies and solid cancers.
by: Brault, L, et al.
Published: (2010)

STUDYING THE ROLE OF PIM KINASES IN FLT3-ITD-INDUCED LEUKEMIA REVEALED PIM1 AS REGULATOR OF CXCL12/CXCR4-MEDIATED HOMING AND MIGRATION
by: Brault, L, et al.
Published: (2009)

Prognostic Significance of in situ Phenotypic Marker Expression in Diffuse Large B-cell Lymphomas
by: Alexandar Tzankov, et al.
Published: (2007-01-01)

Dissecting Proto-Oncogenic PIM Serine/Threonine Kinases in FLT3-ITD-Induced Leukemogenesis: PIM1 Regulates CXCL12/CXCR4-Mediated Homing and Migration
by: Gasser, C, et al.
Published: (2008)

Dissection of PIM serine/threonine kinases in FLT3-ITD-induced leukemogenesis reveals PIM1 as regulator of CXCL12-CXCR4-mediated homing and migration.
by: Grundler, R, et al.
Published: (2009)

PIM kinases as potential therapeutic targets in a subset of peripheral T cell lymphoma cases.
by: Esperanza Martín-Sánchez, et al.
Published: (2014-01-01)

Role and mechanism of PIM family in the immune microenvironment of diffuse large B cell lymphoma
by: Changying Wang, et al.
Published: (2023-03-01)

Mechanisms of Immune Evasion and Immune Modulation by Lymphoma Cells
by: Thomas Menter, et al.
Published: (2018-03-01)

Structure and substrate specificity of the Pim-1 kinase.
by: Bullock, A, et al.
Published: (2005)

Structure and substrate specificity of the Pim-1 kinase
by: Bullock, A, et al.
Published: (2005)

Structural analysis identifies imidazo[1,2-b]pyridazines as PIM kinase inhibitors with in vitro antileukemic activity.
by: Pogacic, V, et al.
Published: (2007)

PIM Kinases as Potential Biomarkers and Therapeutic Targets in Inflammatory Arthritides
by: Elisa Assirelli, et al.
Published: (2024-03-01)

PIM Kinase Inhibition Attenuates the Malignant Progression of Metastatic Hepatoblastoma
by: Janet R. Julson, et al.
Published: (2023-12-01)

PIM Kinases in Multiple Myeloma
by: Jian Wu, et al.
Published: (2021-08-01)

Functional Role and Therapeutic Potential of the Pim-1 Kinase in Colon Carcinoma
by: Ulrike Weirauch, et al.
Published: (2013-07-01)

Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.
by: Bullock, A, et al.
Published: (2009)

Electrostatically Enhanced Association of a Pim Kinase Substrate Revealed by Stochastic Detection
by: Harrington, L, et al.
Published: (2014)

Ruthenium half-sandwich complexes bound to protein kinase Pim-1.
by: Debreczeni, J, et al.
Published: (2006)

Ruthenium half-sandwich complexes bound to protein kinase Pim-1
by: Debreczeni, J, et al.
Published: (2006)

PIM1 genetic alterations associated with distinct molecular profiles, phenotypes and drug responses in diffuse large B‐cell lymphoma
by: Huilai Zhang, et al.
Published: (2022-04-01)

PIM1 and CD79B Mutation Status Impacts the Outcome of Primary Diffuse Large B-Cell Lymphoma of the CNS
by: Jihao Zhou, et al.
Published: (2022-02-01)

Diagnosis and treatment of diffuse large B-cell lymphoma
by: Ulrich J. M. Mey, et al.
Published: (2012-01-01)

Synthesis, kinase inhibitory potencies, and in vitro antiproliferative evaluation of new Pim kinase inhibitors.
by: Akué-Gédu, R, et al.
Published: (2009)

Crystal structure of the PIM2 kinase in complex with an organoruthenium inhibitor.
by: Alex N Bullock, et al.
Published: (2009-10-01)

Thiazolidine derivatives as potent and selective inhibitors of the PIM kinase family.
by: Bataille, C, et al.
Published: (2017)

Selective bisubstrate inhibitors with sub-nanomolar affinity for protein kinase Pim-1.
by: Ekambaram, R, et al.
Published: (2013)

P044: PIM kinases support protumoral and immunosuppressive phenotype and functions of macrophages in classical Hodgkin Lymphoma
by: Maciej Szydłowski, et al.
Published: (2022-10-01)

Anaplastic lymphoma kinase–positive anaplastic large cell lymphoma presenting as diffuse pulmonary infiltrates
by: Shuku Sato, et al.
Published: (2020-10-01)

The Role of PIM Kinases in Pediatric Solid Tumors
by: Janet Rae Julson, et al.
Published: (2022-07-01)

Pim Kinases: Important Regulators of Cardiovascular Disease
by: Sophie Nock, et al.
Published: (2023-07-01)

Targeting PIM Kinases to Improve the Efficacy of Immunotherapy
by: Amber N. Clements, et al.
Published: (2022-11-01)

Stochastic detection of Pim protein kinases reveals electrostatically enhanced association of a peptide substrate.
by: Harrington, L, et al.
Published: (2013)

PB2354: DIFFUSE LARGE B CELL LYMPHOMA IN 65: DIAGNOSTIC, PROGNOSTIC, PROGRESSIVE AND THERAPEUTIC ASPECTS
by: Zaineb Mlayah, et al.
Published: (2023-08-01)

Molecular classification and therapeutics in diffuse large B-cell lymphoma
by: Gaelen Shimkus, et al.
Published: (2023-02-01)

Inhibition of anaplastic lymphoma kinase (ALK) activity provides a therapeutic approach for CLTC-ALK-positive human diffuse large B cell lymphomas.
by: Leandro Cerchietti, et al.
Published: (2011-01-01)

Diffuse Large B-Cell Lymphoma: Recognition of Markers for Targeted Therapy
by: Laura Tomas-Roca, et al.
Published: (2021-05-01)

Insights into molecular pathways for targeted therapeutics in acute leukaemia
by: V Stavropoulou, et al.
Published: (2010-08-01)

An overview of pim kinase as a target in multiple myeloma
by: Zhaoyun Liu, et al.
Published: (2023-05-01)

PIM kinases mediate resistance to cisplatin chemotherapy in hepatoblastoma
by: Raoud Marayati, et al.
Published: (2021-03-01)